Tandem Diabetes Care (TNDM) Return on Capital Employed Growth (3y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -1,962.00 |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 214.00 |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 31.00 |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 355.00 |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -846.00 |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 1,318.00 |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -247.00 |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 362.00 |
| 10 | Tandem Diabetes Care | 1.31 Bn | 739.55 Mn | 136.79 Mn | 1,377.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,377.00 |
| Dec 31, 2025 | -1,899.00 |
| Sep 30, 2025 | -2,432.00 |
| Jun 30, 2025 | -3,000.00 |
| Mar 31, 2025 | -2,843.00 |
| Dec 31, 2024 | -1,689.00 |
| Sep 30, 2024 | -2,347.00 |
| Jun 30, 2024 | -2,288.00 |
| Mar 31, 2024 | -1,989.00 |
| Dec 31, 2023 | -2,971.00 |
| Sep 30, 2023 | -2,402.00 |
| Jun 30, 2023 | -2,183.00 |
| Mar 31, 2023 | -1,646.00 |
| Dec 31, 2022 | -253.00 |
| Sep 30, 2022 | 337.00 |
| Jun 30, 2022 | 1,779.00 |
| Mar 31, 2022 | 3,127.00 |
| Dec 31, 2021 | 3,800.00 |
| Sep 30, 2021 | 5,330.00 |
| Jun 30, 2021 | 5,097.00 |
| Mar 31, 2021 | 7,534.00 |
| Dec 31, 2020 | 11,191.00 |
| Sep 30, 2020 | 9,994.00 |
| Jun 30, 2020 | 10,152.00 |
| Mar 31, 2020 | 8,783.00 |
| Dec 31, 2019 | 10,372.00 |
| Sep 30, 2019 | 10,637.00 |
| Jun 30, 2019 | 5,678.00 |
| Mar 31, 2019 | 3,932.00 |
| Dec 31, 2018 | 3,397.00 |
| Sep 30, 2018 | 1,762.00 |
| Jun 30, 2018 | 1,027.00 |
| Mar 31, 2018 | -780.00 |
| Dec 31, 2017 | -3,226.00 |
| Sep 30, 2017 | -3,514.00 |
| Jun 30, 2017 | -5,450.00 |
| Mar 31, 2017 | -5,070.00 |